Apogee Therapeutics is a clinical-stage biotechnology company founded in 2022 and listed on Nasdaq (Ticker: APGE) that advances novel biologics designed to overcome limitations of existing therapies in immunology and inflammation (I&I) markets. The company's antibody programs incorporate advanced antibody engineering to optimize half-life and other properties, with its most advanced program, Zumilokibart (APG777), being developed for atopic dermatitis and asthma treatment. With four validated targets in its portfolio, Apogee is pursuing best-in-class efficacy and dosing through monotherapies and combinations of novel antibodies to deliver value to patients underserved by current standard-of-care treatments. The company is committed to building an exceptional culture founded on C.O.R.E. values: Caring, Original, Resilient, and Egoless.
Industry
Biotechnology
Company Size
51-200 employees
Founded
2022
Beta · Sourced from candidate reports
Be the first to share your experience with Apogee Therapeutics.
Your reply helps other candidates know what to expect.
